NDRANasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

ENDRA Life Sciences Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$4.75+0.01 (+0.21%)

Close on Oct 19, 2026

Market cap: $11.76M
P/E (TTM): –
Dividend yield: –

ENDRA Life Sciences Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	–	–	–	–	–	0	0	0.01	0.35	0.52
Cost of Revenue	–	–	–	–	–	0	0	0	0.17	–
Gross Profit	–	–	–	–	–	0	0	0.01	0.18	0.28
Research & Development	1.85	3.19	5.00	6.55	5.48	5.92	6.57	4.72	1.93	0.50
Selling, General & Admin	3.91	7.63	5.52	6.60	6.02	5.58	4.27	4.02	2.87	1.58
Selling & Marketing	0.19	0.57	0.82	1.43	1.08	0.58	0.41	0.26	0.12	0.03
General & Administrative	3.72	7.06	4.70	5.17	4.94	5.00	3.86	3.75	2.75	1.54
Operating Expenses	5.76	11	11	13	11	12	11	9.03	4.80	2.07
Operating Income	-5.76	-11	-11	-13	-11	-12	-11	-9.02	-4.63	-1.79
Interest Expense	–	–	–	–	–	–	–	0	0.00	0.07
Other Non-Operating Income	-1.26	-0.69	0.46	-0.02	0.27	-0.22	-2.46	-0.78	-0.75	–
Asset Impairment Charges	–	–	–	–	–	–	0	0.29	0	–
Gain (Loss) on Sale of Assets	–	-0.01	–	–	–	–	–	–	–	–
Pretax Income	-7.03	-12	-10	-13	-11	-12	-13	-9.80	-5.38	-2.78
Income Tax Expense	–	0	0	0	0	0	0	0	0	0
Net Income incl. Noncontrolling Interests	–	-12	-10	13	11	12	-13	-9.80	-5.38	-2.78
Net Income	-7.03	-12	-10	-13	-11	-12	-13	-9.80	-5.38	-2.78
Preferred Dividends	–	–	–	0	0	0	–	–	–	–
Net Income to Common	–	–	–	-13	-11	-12	-18	-9.80	–	–
EPS (Basic)(per share)	-8.93	-56.94	–	-4.56	-5.55	-0.63	-2.34	-2.17	-1.95	-3.84
EPS (Diluted)(per share)	-8.93	-56.94	-2,766.85	–	–	-0.63	-2.34	-2.17	-1.95	-3.84
Shares Outstanding (Basic, Weighted)(shares)	0.79	0.20	–	–	–	19	7.50	4.50	2.76	0.72
Shares Outstanding (Diluted, Weighted)(shares)	0.79	0.20	0.00	–	–	19	7.50	4.50	2.76	0.72
EBITDA	-5.72	-11	-10	-13	-11	-11	-11	-8.95	-4.56	-1.73

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -291.6%

Financial strength

Current ratio: 7.10
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 221.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.86
Dividend yield: –